|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||4.2850 - 4.3000|
|52-week range||4.1889 - 10.8700|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||0.13|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Husband and wife, Mr and Mrs Tan, medical specialists in their respective fields, saw 75 houses in three months when they were house-hunting in 2021. “It was the peak of the craziness for house buying in 2021,” relates Mrs Tan. “We got gazumped twice and were near the end of our tether when we decided to just look at off-plan options because we couldn’t find any house that we liked that was already built.”Many of the houses they saw were old and in need of refurbishment. “This was in 2021, and i
Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) were down more than 16% as of 2:15 p.m. on Tuesday. The pharmaceutical stock has been in decline for several months, and in May, it announced it was suing the federal government, saying the Food and Drug Administration (FDA) passed trade secrets about sleep-disorder drug Hetlioz and schizophrenia therapy Fanapt, Vanda's only marketed therapies, to generic drug competitors. Various exchange-traded funds (ETFs) use the index as a basis for choosing stocks to invest in, so that means likely lower trading for Vanda.
The heavy selling pressure might have exhausted for Vanda (VNDA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.